Navigation Links
Phase 3 data show viral cure rates achieved in a broad range of patients with genotype-1 hepatitis C taking investigational compound faldaprevir plus PegIFN/RBV
Date:11/2/2013

RIDGEFIELD, Conn., Nov. 2, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced new data from its Phase 3 clinical trial program, STARTVerso™, which evaluates the investigational protease inhibitor, faldaprevir, in combination with pegylated interferon and ribavirin (PegIFN/RBV). The Phase 3 clinical program includes trials in treatment-naive (STARTVerso™1&2 - NCT01343888, NCT01297270), treatment-experienced (STARTVerso™3 - NCT01358864), and HIV/HCV coinfected (STARTVerso™4 - NCT01399619) patients with genotype-1 (GT1) hepatitis C (HCV). The primary efficacy endpoint of all trials is viral cure 12 weeks after the conclusion of treatment (SVR12).

In a pooled analysis of treatment-naive, genotype 1 patients (STARTVerso™1&2), 73% (382/521) and 72% (378/524) of all patients treated with 120mg or 240mg of faldaprevir once-daily, both in combination with PegIFN/RBV, respectively, achieved SVR12. In comparison, 50% (131/264) of patients treated with PegIFN/RBV alone achieved SVR12. Also in the pooled analysis, 84% (436/521) of patients who received a regimen including 120mg of faldaprevir once-daily were eligible for an overall shortened time on treatment of 12 weeks on faldaprevir and 24 weeks on PegIFN/RBV. Of these patients, 83% (362/436) achieved SVR12.

In treatment-experienced patients (STARTVerso™3), 12 weeks of faldaprevir-based treatment (240mg once-daily), in combination with PegIFN/RBV, demonstrated SVR12 of 70% (69/99) in patients who relapsed on previous HCV treatment, compared to
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Research and Markets has announced the addition ... report to their offering. Benefiting ... for medical expenses, the Chinese orthopedic instrument market demand ... CAGR of 19.2% during 2009-2013. Trauma products, spine products ... instruments in China , of which ...
(Date:8/29/2014)... Research and Markets has announced the addition ... Pharmaceutical Equipment Market in China, 2014-2018" report to ... Forecast of Pharmaceutical Equipment Market in China ... pharmaceutical equipment industry in the aspects of current ... performance of domestic major enterprises, as well as offers ...
(Date:8/29/2014)... 29, 2014  Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... it intends to release its financial results for the ... 2014 after market trading ends on Tuesday, September 9, ... call for 4:30 p.m. U.S. EDT on Tuesday, September ... to review the Company,s financial results, commercial partnerships, and ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
(Date:8/29/2014)... Denver, Colorado (PRWEB) August 29, 2014 ... Treatment. This is an absolutely unique method of curing ... The new program was created by Dr. Gary M. ... The health specialist started to become interested in alternative ... realized that classical remedies cannot be effective in all ...
(Date:8/29/2014)... 29, 2014 Dr. Mohebi’s lecture on ... talked about introducing these cutting edge techniques at their ... the FUE Research Committee has allowed him the ability ... is possible with modern technology. Dr. Mohebi stated, “We ... FUE devices that facilitate extraction and implantation of hair ...
(Date:8/29/2014)... reported by CNN.com in the article Prescription Drug Abuse: ... you need help for a prescription drug abuse problem can ... that if you simply try to find general help for ... the information that is available online. Although the information available ... possible to get help. The statistics from SAMSHA remind the ...
(Date:8/29/2014)... August 30, 2014 Market Research ... 2009-2019 is a professional and in-depth market survey ... report firstly reviews the basic information of Glass ... The report then explores global and China’s top ... capacity, Production value, and market share etc. , ...
(Date:8/29/2014)... Del Mar, CA (PRWEB) August 29, 2014 ... “oyasumi bra,” a bra developed by a Tokyo clothing store ... bed in the hopes of rectifying or diminishing their problem. ... has treated men with the problem. While many people only ... is actually a fairly common condition among men of all ...
Breaking Medicine News(10 mins):Health News:New Natural Multiple Sclerosis Treatment Review Reveals Gary M. Levin’s Unique Cure 2Health News:Parsa Mohebi M.D., Beverly Hills Hair Restoration Surgeon Gives Inspiring Lecture on Groundbreaking Techniques in Follicular Unit Extraction 2Health News:What to Know When Seeking Drug Addiction Help 2Health News:What to Know When Seeking Drug Addiction Help 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:New Bra Created for Men with Gynecomastia, But Will It Work? 2Health News:New Bra Created for Men with Gynecomastia, But Will It Work? 3
... in an extremely exciting phase right now. We are ... formed and are starting clinical trials in different areas," ... first-in-human study was just initiated for Parkinson,s disease patients ... NeuroNova. The drug, which is administered into the fluid-filled ...
... ST. PAUL, Minn., May 21 Three HealthEast ... agreed to pay the federal government a total ... tam") lawsuit alleging Medicare fraud involving a certain ... hospitals are the first hospitals to settle charges ...
... FRANCISCO -- Mayo Clinic researchers have found that bipolar ... as diabetes, depression, asthma or coronary artery disease. These ... claim costs. Specialty care costs (the costs of seeing ... for bipolar patients. Results of this review are being ...
... May 21 Elimination of funding for ... by the Senate Republican budget plan would end a ... rate of health care cost increases, improving quality of ... today.For the past two years the small "think tank" ...
... HMS today announced that it had been awarded contracts ... million lives to the company,s portfolio. HMS will be providing ... party recovery and cost avoidance -- to Citrus Health Care, ... (NY); Health First (NY); Health Plan of Michigan, Inc. (MI); ...
... (May 21, 2009) In comparing ultrasound with other medical ... review of published studies in the May/June issue of ... of ultrasound to provide an accurate diagnosis more cost ... the 1950s, ultrasound has been utilized mostly in hospital settings. ...
Cached Medicine News:Health News:Minnesota Hospitals Pay $2.28 Million to Settle Medicare Fraud Charges Involving Kyphoplasty 2Health News:Minnesota Hospitals Pay $2.28 Million to Settle Medicare Fraud Charges Involving Kyphoplasty 3Health News:Senate Republican Budget Would End Health Initiatives That Save Lives and Money 2Health News:Senate Republican Budget Would End Health Initiatives That Save Lives and Money 3Health News:Senate Republican Budget Would End Health Initiatives That Save Lives and Money 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: